Patient characteristics and outcomes
| Patient UPN . | Age, y . | Disease location (size at study entry) . | KPS at study entry . | Prior lines of therapy, n . | Bridging therapy . | Cell dose, M . | CRS max grade . | Symptoms (NT max grade)* . | Intervention for CRS/NT . | Best Response . | Duration of response, d . | Current status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 286 | 53 | Left temporal lobe (0.6 cm) | 90 | 3 | High-dose methotrexate-based chemotherapy | 200 | 2 | Headache (3), agitation (1), restlessness (1) | Toci and Dex | CR | 273 | Progressed/alive |
| 310† | 53 | Posterior corpus callosum (1.6 cm) | 80 | 6 | Pomalidomide | 115‡ | 1 | Headache (2), dizziness (2), memory impairment (1) | None | SD | 13 | Off protocol therapy/alive, on maintenance pomalidomide |
| 272 | 47 | Right temporal lobe (3 cm), left temporal lobe (1.5 cm), and right basal ganglia (3 cm) | 70 | 12 | Brain radiation; steroids | 200 | 1 | Tremor (1), dysarthria (1), hallucinations (1) | None | SD | 32 | Progressed/lost to follow-up |
| 346 | 49 | Right temporal lobe (0.9 cm) | 90 | 2 | None | 600 | 2 | Concentration impairment (1), dysphasia (1) | Toci and Dex | CR | 520§ | CR/alive |
| 475 | 42 | Left basal ganglia (0.5 cm) | 90 | 5 | Brain radiation; steroids | 600 | 1 | Seizure (1), dizziness (1) | None | CR | 43 | Off protocol therapy/alive, on maintenance lenalidomide |
| Patient UPN . | Age, y . | Disease location (size at study entry) . | KPS at study entry . | Prior lines of therapy, n . | Bridging therapy . | Cell dose, M . | CRS max grade . | Symptoms (NT max grade)* . | Intervention for CRS/NT . | Best Response . | Duration of response, d . | Current status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 286 | 53 | Left temporal lobe (0.6 cm) | 90 | 3 | High-dose methotrexate-based chemotherapy | 200 | 2 | Headache (3), agitation (1), restlessness (1) | Toci and Dex | CR | 273 | Progressed/alive |
| 310† | 53 | Posterior corpus callosum (1.6 cm) | 80 | 6 | Pomalidomide | 115‡ | 1 | Headache (2), dizziness (2), memory impairment (1) | None | SD | 13 | Off protocol therapy/alive, on maintenance pomalidomide |
| 272 | 47 | Right temporal lobe (3 cm), left temporal lobe (1.5 cm), and right basal ganglia (3 cm) | 70 | 12 | Brain radiation; steroids | 200 | 1 | Tremor (1), dysarthria (1), hallucinations (1) | None | SD | 32 | Progressed/lost to follow-up |
| 346 | 49 | Right temporal lobe (0.9 cm) | 90 | 2 | None | 600 | 2 | Concentration impairment (1), dysphasia (1) | Toci and Dex | CR | 520§ | CR/alive |
| 475 | 42 | Left basal ganglia (0.5 cm) | 90 | 5 | Brain radiation; steroids | 600 | 1 | Seizure (1), dizziness (1) | None | CR | 43 | Off protocol therapy/alive, on maintenance lenalidomide |
Dex, dexamethasone; KPS, Karnofsky Performance Status; max, maximum; NA, not applicable; SD, stable disease; Toci, tocilizumab; UPN, unique patient number.
Highest grade possibly, probably, or definitely related to T-cell infusion. Symptoms experienced by UPN 346 were probably related to T-cell infusion, whereas all other symptoms were possibly related.
The patient declined all research studies on the trial after receiving CD19CAR T cells and received pomalidomide at day 28, which took them off protocol therapy.
The manufactured dose for UPN 310 was 115M.
Most recent disease assessment based on clinical assessment.